StockData
NewAmsterdam Pharma Co N.V. logo

NewAmsterdam Pharma Co N.V. (NAMS) shareholders

NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$19.39−0.07 (-0.36%)

Close on Nov 17, 2026Market cap $2.32BP/E –Yield –

Ownership

Who owns NewAmsterdam Pharma's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
1 buys · 43 sales
Net sold $63.03M

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Capital World Investors12,188,37710.40%13G (passive) amendmentMay 29, 2026
FMR LLC
Joint filing with Abigail P. Johnson (10.00%)
11,941,76310.00%13G (passive) amendmentSep 30, 2026
RA Capital Management, L.P.
Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more
11,063,1259.90%13G (passive) amendmentMar 31, 2025
Peter Kolchinsky
Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more
10,875,4549.90%13G (passive) amendmentDec 31, 2024
Fhmlsp, L.L.C.
Joint filing with Frazier Life Sciences Public Fund, L.P. (8.70%), Fhmlsp, L.P. (8.70%) and 5 more
10,424,2248.70%13D (active) amendmentSep 18, 2026
ForGrowth NAP B.V.9,316,9148.30%13D (active) amendmentSep 26, 2025
Abigail P. Johnson
Joint filing with FMR LLC (7.60%)
8,765,8117.60%13G (passive) amendmentMar 31, 2026
Frazier Life Sciences Public Fund, L.P.
Joint filing with Fhmlsp, L.P. (7.70%), Fhmlsp, L.L.C. (7.70%) and 5 more
8,623,9397.70%13D (active) amendmentNov 1, 2025
Patrick J. Heron
Joint filing with Fhmls X, L.P. (6.50%), Fhmls X, L.L.C. (6.50%) and 5 more
7,327,9376.50%13D (active) amendmentAug 18, 2025
Viking Global Investors LP
Joint filing with Viking Global Opportunities Parent GP LLC (6.50%), Halvorsen Ole Andreas (6.50%) and 2 more
6,978,5346.50%13G (passive) amendmentDec 31, 2024

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Johannes Jacob Pieter KasteleinChief Scientific Officer, Director122,802Oct 2, 2026
Michael H. DavidsonChief Executive Officer, Director1,078,638Sep 15, 2026
Robert William GunningVice President, Controller3,200Sep 3, 2026
Louise Frederika KooijChief Accounting Officer49,353Jul 22, 2026
Mayur Ian SomaiyaChief Financial Officer98,166Jan 22, 2026
Douglas F. KlingChief Operating Officer44,000Jul 17, 2025
Michael F. Marino IIISee Remarks55,000Jun 3, 2025
Juliette Berangere AudetSee Remarks15,104May 2, 2025
William A. Jones JrChief Commercial Officer43,000Jan 7, 2025
John W. SmitherDirector8,760Sep 9, 2026
Louis G. LangeDirector10,806Mar 12, 2026
der Kamp Hilde Johanna vanDirector10,360Jan 9, 2026
William LewisDirector10,360Jan 9, 2026
Mark C. McKennaDirector10,360Jan 9, 2026
Adele M. GulfoDirector14,260Jan 9, 2026
James N. TopperDirector6,829,524Sep 17, 2025
Growth Opportunities Fund I. Cooperatief U.A. Forbion10% owner–Jan 2, 2025
Growth Management B.V. Forbion10% owner11,316,472Jan 2, 2025
NAP B.V. ForGrowth10% owner10,656,172Jan 2, 2025
IV Management B.V. Forbion10% owner10,760,928Jan 2, 2025
Capital Fund IV Cooperatief U.A. Forbion10% owner10,686,018Jan 2, 2025
Bain Capital Life Sciences III General Partner, LLC10% owner–Dec 17, 2024
BCLS Fund III Investments, LP10% owner–Dec 17, 2024
Bain Capital Life Sciences Investors II, LLC10% owner–Dec 17, 2024
BCIP Life Sciences Associates, LP10% owner–Dec 17, 2024
BCLS II Investco, LP10% owner–Dec 17, 2024
Bain Capital Life Sciences Investors, LLC10% owner–Dec 17, 2024
BCLS II Investco (GP), LLC10% owner–Dec 17, 2024
Bain Capital Life Sciences Fund II, L.P.10% owner–Dec 17, 2024
Bain Capital Life Sciences Fund III, L.P.10% owner10,473,913Dec 17, 2024

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Johannes Jacob Pieter Kastelein
Chief Scientific Officer, Director
Sep 30, 2026Sale(10b5-1 plan)−50,246$25.03$1.26M69,302
Johannes Jacob Pieter Kastelein
Chief Scientific Officer, Director
Sep 30, 2026Option exercise+50,246––119,548
Michael H. Davidson
Chief Executive Officer, Director
Sep 14, 2026Buy+10,000$22.65$226.50K792,923
John W. Smither
Director
Sep 4, 2026Sale−1,600$25.32$40.51K8,760
Robert William Gunning
Vice President, Controller
Sep 1, 2026Award+3,200––3,200
Johannes Jacob Pieter Kastelein
Chief Scientific Officer, Director
Aug 24, 2026Option exercise+125,000––194,302
Johannes Jacob Pieter Kastelein
Chief Scientific Officer, Director
Aug 24, 2026Sale(10b5-1 plan)−125,000$26.91$3.36M69,302
Louise Frederika Kooij
Chief Accounting Officer
Jul 20, 2026Option exercise+25,000$11.90$297.50K49,353
Louise Frederika Kooij
Chief Accounting Officer
Jul 20, 2026Option exercise+80,000$11.17$893.60K129,353
Louise Frederika Kooij
Chief Accounting Officer
Jul 20, 2026Sale(10b5-1 plan)−70,200$29.96$2.10M59,153
Louise Frederika Kooij
Chief Accounting Officer
Jul 20, 2026Sale(10b5-1 plan)−31,885$31.05$990.03K27,268
Louise Frederika Kooij
Chief Accounting Officer
Jul 20, 2026Sale(10b5-1 plan)−2,915$31.71$92.43K24,353
Louise Frederika Kooij
Chief Accounting Officer
Jun 22, 2026Sale(10b5-1 plan)−39,700$30.20$1.20M24,653
Louise Frederika Kooij
Chief Accounting Officer
Jun 22, 2026Option exercise+25,000$10.90$272.50K49,353
Louise Frederika Kooij
Chief Accounting Officer
Jun 22, 2026Option exercise+15,000$11.90$178.50K64,353
Louise Frederika Kooij
Chief Accounting Officer
Jun 22, 2026Sale(10b5-1 plan)−300$30.73$9.22K24,353
Louise Frederika Kooij
Chief Accounting Officer
May 26, 2026Option exercise+60,000$10.00$600.00K84,353
Louise Frederika Kooij
Chief Accounting Officer
May 26, 2026Sale(10b5-1 plan)−65,000$35.69$2.32M24,353
Louise Frederika Kooij
Chief Accounting Officer
May 26, 2026Option exercise+5,000$10.90$54.50K89,353
Louis G. Lange
Director
Mar 11, 2026Sale−44,173$30.41$1.34M10,806
Louis G. Lange
Director
Mar 11, 2026Sale−446$31.23$13.93K10,360
Louis G. Lange
Director
Mar 9, 2026Option exercise+44,619$11.50$513.12K54,979
Johannes Jacob Pieter Kastelein
Chief Scientific Officer, Director
Mar 9, 2026Option exercise+101,409––170,711
Johannes Jacob Pieter Kastelein
Chief Scientific Officer, Director
Mar 9, 2026Sale(10b5-1 plan)−101,409$30.29$3.07M69,302
Louis G. Lange
Director
Mar 6, 2026Sale−28,186$29.41$828.95K0
Johannes Jacob Pieter Kastelein
Chief Scientific Officer, Director
Mar 6, 2026Sale(10b5-1 plan)−94,124$30.32$2.85M69,302
Johannes Jacob Pieter Kastelein
Chief Scientific Officer, Director
Mar 6, 2026Option exercise+94,124––163,426
Johannes Jacob Pieter Kastelein
Chief Scientific Officer, Director
Mar 5, 2026Sale(10b5-1 plan)−104,467$30.30$3.17M69,302
Johannes Jacob Pieter Kastelein
Chief Scientific Officer, Director
Mar 5, 2026Option exercise+104,467––173,769
Michael H. Davidson
Chief Executive Officer, Director
Mar 2, 2026Option exercise+443,707––617,851
Michael H. Davidson
Chief Executive Officer, Director
Mar 2, 2026Sale−443,707$33.25$14.75M174,144
Michael H. Davidson
Chief Executive Officer, Director
Feb 26, 2026Sale(10b5-1 plan)−17,924$34.44$617.30K174,144
Michael H. Davidson
Chief Executive Officer, Director
Feb 26, 2026Sale(10b5-1 plan)−165,408$33.63$5.56M477,783
Michael H. Davidson
Chief Executive Officer, Director
Feb 26, 2026Option exercise+183,332––643,191
Michael H. Davidson
Chief Executive Officer, Director
Feb 25, 2026Sale(10b5-1 plan)−1,300$36.68$47.68K459,859
Michael H. Davidson
Chief Executive Officer, Director
Feb 25, 2026Sale(10b5-1 plan)−10,436$35.96$375.28K461,159
Michael H. Davidson
Chief Executive Officer, Director
Feb 25, 2026Sale(10b5-1 plan)−46,517$35.11$1.63M471,595
Michael H. Davidson
Chief Executive Officer, Director
Feb 25, 2026Option exercise+58,253––518,112
Michael H. Davidson
Chief Executive Officer, Director
Feb 24, 2026Sale(10b5-1 plan)−3,161$36.46$115.25K459,859
Michael H. Davidson
Chief Executive Officer, Director
Feb 24, 2026Sale(10b5-1 plan)−61,547$36.13$2.22M463,020
Michael H. Davidson
Chief Executive Officer, Director
Feb 24, 2026Option exercise+64,708––524,567
Johannes Jacob Pieter Kastelein
Chief Scientific Officer, Director
Feb 20, 2026Sale−14,692$35.00$514.22K84,289
Johannes Jacob Pieter Kastelein
Chief Scientific Officer, Director
Feb 20, 2026Sale−30,789$35.46$1.09M53,500
Louise Frederika Kooij
Chief Accounting Officer
Jan 28, 2026Sale(10b5-1 plan)−32,612$31.80$1.04M24,353
Louise Frederika Kooij
Chief Accounting Officer
Jan 28, 2026Option exercise+32,612$10.90$355.47K56,965
Louise Frederika Kooij
Chief Accounting Officer
Jan 27, 2026Option exercise+39,816$10.90$433.99K64,169
Louise Frederika Kooij
Chief Accounting Officer
Jan 27, 2026Sale(10b5-1 plan)−39,816$32.62$1.30M24,353
Louise Frederika Kooij
Chief Accounting Officer
Jan 26, 2026Sale(10b5-1 plan)−309$33.45$10.34K24,353
Louise Frederika Kooij
Chief Accounting Officer
Jan 26, 2026Sale(10b5-1 plan)−34,091$32.77$1.12M24,662
Louise Frederika Kooij
Chief Accounting Officer
Jan 26, 2026Option exercise+34,400$10.90$374.96K58,753
Louise Frederika Kooij
Chief Accounting Officer
Jan 23, 2026Sale(10b5-1 plan)−12,767$34.37$438.80K24,353
Louise Frederika Kooij
Chief Accounting Officer
Jan 23, 2026Sale(10b5-1 plan)−25,405$33.44$849.54K37,120
Louise Frederika Kooij
Chief Accounting Officer
Jan 23, 2026Option exercise+38,172$10.90$416.07K62,525
Mayur Ian Somaiya
Chief Financial Officer
Jan 21, 2026Option exercise+39,784$9.26$368.40K98,166
Mayur Ian Somaiya
Chief Financial Officer
Jan 21, 2026Sale(10b5-1 plan)−15,422$33.25$512.78K82,744
Mayur Ian Somaiya
Chief Financial Officer
Jan 21, 2026Sale(10b5-1 plan)−24,362$33.80$823.44K58,382
Mayur Ian Somaiya
Chief Financial Officer
Jan 20, 2026Sale(10b5-1 plan)−900$30.64$27.58K117,698
Mayur Ian Somaiya
Chief Financial Officer
Jan 20, 2026Sale(10b5-1 plan)−39,712$31.78$1.26M77,986
Mayur Ian Somaiya
Chief Financial Officer
Jan 20, 2026Sale(10b5-1 plan)−19,604$32.38$634.78K58,382
Mayur Ian Somaiya
Chief Financial Officer
Jan 20, 2026Option exercise+60,216$9.26$557.60K118,598

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
12M shares short
Days to cover
8.3
At 1M shares a day
Change since last report
-14.9%
From 14M shares
Short volume, 20 days
37.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of NewAmsterdam Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 115,916 shares on Sep 24, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Johannes Jacob Pieter Kastelein
Affiliate
Aug 25, 2026250,000$6.97MAug 25, 2026Option Exercise
Johannes Jacob Pieter Kastelein
Affiliate
Aug 24, 2026125,000$3.48MAug 24, 2026Option Exercise
Louise Frederika Kooij
Officer
May 26, 2026210,000$7.44MMay 26, 2026Stock Option Exercise
Louis G. Lange
Affiliate
Mar 11, 202644,619$1.40MMar 11, 2026Warrant Exercise
Louis G. Lange
Affiliate
Mar 6, 202628,186$878.84KMar 6, 2026RSU Award
Johannes Jacob Pieter Kastelein
Affiliate
Mar 5, 2026300,000$9.35MMar 2, 2026Option Exercise
Michael H. Davidson
Affiliate
Mar 2, 2026443,707$15.73MMar 2, 2026Option Exercise
Michael H. Davidson
Affiliate
Feb 24, 2026750,000$27.13MFeb 24, 2026Option Exercise
Johannes Jacob Pieter Kastelein
Officer, Director
Feb 20, 202645,481$1.58MFeb 20, 2026Vesting of RSU Grant
Mayur Ian Somaiya
Affiliate
Jan 20, 2026200,000$6.33MJan 20, 2026Stock Option Exercise
Michael H. Davidson
affiliate
Jan 7, 202611,582$410.89KJan 7, 2026Vesting of RSU Grant
Douglas F. Kling
Affiliate
Jan 6, 2026300,000$10.04MJan 6, 2026Stock Option Exercise
Mayur Ian Somaiya
affiliate
Jan 5, 20265,118$170.17KJan 5, 2026Vesting of RSU Grant
Johannes Kastelein
Affiliate
Jan 5, 20266,000$199.50KJan 5, 2026Vesting of RSU Grant
Louise Frederika Kooij
affiliate
Jan 5, 20262,647$88.01KJan 5, 2026Vesting of RSU Grant

See a number that looks wrong?